Future of the Irritable Bowel Syndrome (IBS) Treatment Market: Strategic Analysis and Forecast to 2034

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Irritable Bowel Syndrome (IBS) Treatment Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The market size for treating irritable bowel syndrome (IBS) has seen a swift expansion in the previous years. It's projected to surge from $2.79 billion in 2024 to $3.07 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 10.2%. The progress during the historical period can be credited to factors such as the rising incidence of IBS, heightened patient awareness, the impact of stress and lifestyle elements, the presence of patient advocacy and support groups, as well as healthcare reimbursement policies.

Irritable Bowel Syndrome (IBS) Treatment Market Size Forecast: What's the Projected Valuation by 2029?
Over the coming years, we forecast an accelerated expansion for the irritable bowel syndrome (IBS) treatment market. The market size is projected to reach $4.93 billion by 2029, prospering at a compound annual growth rate (CAGR) of 12.5%. This growth within the forecasted period may be a result of patient-focused healthcare models, emerging microbial therapies, the adoption of blockchain in healthcare, patient-reported outcomes (pros), accelerated approval programs, and interoperability of health data. The forthcoming period will bring major trends like the incorporation of digital health solutions, progression in diagnostic technologies, a surge in investments for research and development, collaborations and strategic partnerships, as well as the advent of non-pharmacological therapies.

View the full report here:
https://www.thebusinessresearchcompany.com/report/irritable-bowel-syndrome-ibs-treatment-global-market-report

What Are the Drivers Transforming the Irritable Bowel Syndrome (IBS) Treatment Market?
There's an anticipated growth in the irritable bowel syndrome treatment market primarily fueled by the increasing instances of Irritable Bowel Syndrome (IBS). IBS is a persistent gastrointestinal disorder that impacts the large intestine (colon). Poor lifestyle choices, unhealthy diet, pollution exposure, and high stress levels contribute to the increasing prevalence of IBS. IBS treatments aim to alleviate the intensity and regularity of IBS symptoms, enhance life quality, and empower patients to control their conditions more effectively. For instance, the International Foundation for Gastrointestinal Disorders (IFFGD), which is a non-profit education and research organization based in the US, approximates that 5-10% of the world's population will be affected by IBS in 2023 and between 25 and 45 million people in the US alone will suffer from IBS. Hence, the growth of the IBS treatment market can be attributed to the increasing prevalence of IBS.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=11978&type=smp

What Long-Term Trends Will Define the Future of the Irritable Bowel Syndrome (IBS) Treatment Market?
Product advancements are emerging as a front-runner in trends within the irritable bowel syndrome (IBS) market. Big players within the irritable bowel syndrome (IBS) industry are honing their focus on the creation of cutting-edge, innovative products to fortify their market stronghold. For instance, in April 2022, Ardelyx, a biotech firm based in the U.S., unveiled IBSRELA, a trailblazer in the treatment of IBS-C in adults. As the inaugural and sole NHE3 inhibitor for the treatment of adult IBS-C, IBSRELA marks the first medicine from Ardelyx to achieve FDA clearance. This is also the first new therapy for IBS-C (irritable bowel syndrome-constipation) in nearly a decade, providing a considerable treatment breakthrough for the constipation, bloating, and abdominal discomfort symptomatic of this debilitating condition.

Which Segments in the Irritable Bowel Syndrome (IBS) Treatment Market Offer the Most Profit Potential?
The irritable bowel syndrome (IBS) treatment market covered in this report is segmented -

1) By Drug Type: Lubiprostone, Linaclotide, Eluxadoline, Rifaximin, Alosetron, Other Drugs
2) By Indication: IBS With Constipation, IBS With Diarrhea, IBS With Alternating Constipation And Diarrhea
3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies
4) By End-Users: Hospitals, Clinics, Homecare Settings

Subsegments:
1) By Lubiprostone: Chronic Idiopathic Constipation Treatment, Irritable Bowel Syndrome with Constipation (IBS-C) Treatment
2) By Linaclotide: IBS-C Treatment, Chronic Idiopathic Constipation Treatment
3) By Eluxadoline: IBS with Diarrhea (IBS-D) Treatment
4) By Rifaximin: IBS-D Treatment, Small Intestinal Bacterial Overgrowth (SIBO) Treatment
5) By Alosetron: Severe IBS-D Treatment for Women
6) By Other Drugs: Prucalopride, Tenapanor, Plecanatide

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=11978&type=smp

Which Firms Dominate the Irritable Bowel Syndrome (IBS) Treatment Market by Market Share and Revenue in 2025?
Major companies operating in the irritable bowel syndrome (IBS) treatment market include Pfizer Inc., Johnson & Johnson Services Inc., AbbVie Inc., Novartis AG, AstraZeneca plc, Abbott Laboratories, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Astellas Pharma Inc., Biogen Inc., Bausch Health Companies Inc., Ironwood Pharmaceuticals Inc., Sebela Pharmaceuticals Inc., Prometheus Laboratories Inc., RedHill Biopharma Ltd., Ardelyx Inc., Cosmo Technologies Ltd., Renexxion Ireland Ltd., 4D Pharma plc, Biora Therapeutics Inc.

Which Regions Offer the Highest Growth Potential in the Irritable Bowel Syndrome (IBS) Treatment Market?
North America was the largest region in the irritable bowel syndrome (IBS) treatment market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the irritable bowel syndrome (IBS) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=11978

This Report Supports:
1. Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2. Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3. Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4. Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.